> The 19% result is real and independently replicated in over 1,800 patients, but whether bepirovirsen reduces the 1.1 million HBV deaths per year depends on trials in populations that weren't enrolled here.
Do we know, how many of those deaths are due to limitations of existing treatments, versus how many are due to health care access issues?
This comment smells like Claude.
Agreed.
>AI Engineer @Varnan Labs
Bingo. A glance at their comment history shows this is a pattern for them
> The 19% result is real and independently replicated in over 1,800 patients, but whether bepirovirsen reduces the 1.1 million HBV deaths per year depends on trials in populations that weren't enrolled here.
Do we know, how many of those deaths are due to limitations of existing treatments, versus how many are due to health care access issues?